In this review, we will discuss the most important molecular mutations, such as CD33, FLT3-ITD, BCL2, and IDH1/2 mutations and aberrant hedgehog signaling, and the associated targeted approaches in patients with AML, along with the US FDA approval status of each approach. This evidence concerns the gene CD33 and acute myeloid leukemia.